Chinese loans to Latin America plunge as virus strains ties

Sunday, February 21, 2021 | Joshua Goodman, Associated Press

In this March 30, 2020 file photo, Venezuela's Foreign Minister Jorge Arreaza, wearing protective gloves as a preventive measure against the spread of the new coronavirus, holds a Venezuelan and Chinese flag as medical specialists and supplies arrive from China at the Simon Bolivar International Airport in La Guaira, Venezuela. While the pandemic has opened the door to much-welcomed Chinese aid in Latin America and Caribbean, it’s also made it harder for governments to pay their bills to Beijing, due to a deep recession last year wiped out nearly a decade’s worth of growth, according to International Monetary Fund data. (AP Photo/Matias Delacroix, File)

MIAMI (AP) — It seemed like a match made in finance heaven.

In 2010, China, its economy roaring and state companies looking to expand globally, set its eyes on Latin America, a region starved of capital but rich in natural resources the Asian giant lacked. The result: a record $35 billion in state-to-state loans that year.

Fast forward a decade and the once-torrid relationship is starting to mature in ways that suggest China may be growing wary of its once do-no-wrong partner.

For the first time in 15 years, China’s two biggest policy banks — the China Development Bank (CDB) and the Export-Import Bank of China — made no new loans to the region in 2020, capping a multi-year slump driven by Latin America’s worsening economic slide.

The data comes from a new repor t by the Inter-American Dialogue, a Washington think tank, and Boston University’s Global Development Policy Center, both of which have been tracking for years China’s yuan diplomacy in Washington’s backyard.

China’s growing economic and diplomatic influence in the region has worried U.S. policymakers, who have been at a loss to counter its rise. The task now falls to the Biden administration, which has warned that the Chinese footprint in the region is a national security threat. But with China having displaced the U.S. as the top trading partner of several South American nations, catching up will be no easy task.

Meanwhile, the U.S. may have fallen even farther behind during the pandemic, when China donated more than $215 million in supplies — from surgical gloves to thermal imaging technologies — to allies in the region, according to the research. By comparison, the United State Agency for International Development and State Department has provided $153 million. China also conducted clinical trials or plans to manufacture vaccines in five countries — Argentina, Brazil, Chile, Mexico and Peru.

“Without a doubt part of the region’s COVID response has a Chinese face,” said Rebecca Ray, a Boston University economist and one of the authors of the new report. “It’s a missed opportunity for the U.S. but since the bottoming out of American manufacturing in the 1990s there’s really no way to compete. Many of the same medical supplies China ships to Latin America we buy from China as well.”

But while the pandemic has opened the door to much-welcomed Chinese aid, it’s also made it harder for governments to pay their bills to Beijing. A deep 7.4% recession in the Latin America and Caribbean last year wiped out nearly a decade’s worth of growth, according to International Monetary Fund data.

With borrowers squeezed, China has taken a hit. Last year, Ecuador negotiated to delay for a year nearly $900 million in debt payments serviced by oil shipments. Venezuela — by far the region’s biggest borrower — is believed to have received a similar grace period. At the same time,

“With the region facing unprecedented challenges, China is unlikely to lend any more for now,” said Margaret Myers, head of the Asia-Latin America program at the Dialogue. “Instead it has to grapple with its own problematic portfolio."

The slowdown in lending to Latin America reflects a broader, global pullback, as China turns inward to bolster its own recovery efforts amid the pandemic. The ruling Communist Party has lent billions of dollars to build ports, railways and other infrastructure across Asia to Africa, Europe and Latin America in order to expand China’s access to markets and resources.

But Beijing has grown more cautious after some borrowers struggled to repay loans. Officials say they will examine projects and financing more carefully.

The China Development Bank and the foreign ministry didn’t respond to questions about the reasons for the decline in Chinese loans to Latin America.

Even though lending has dried up, Chinese buying of Latin America's soybeans, iron ore and other commodities remained robust, at an estimated $136 billion. That’s despite a sharp rise of China's purchases of American farm goods, a promise reached with the Trump administration to end a debilitating trade war.

Chinese state-run energy companies also aggressively bought up at fire sale prices energy assets from exiting Western investors. Overall, Chinese mergers and acquisitions surged to $7 billion in 2020, nearly double the amount of activity in 2019, according to the research.

Among the deals: the sale of Peru’s largest electric company by San Diego, CA-based Sempra Energy to China Three Gorges Corp. Another $5 billion deal giving State Grid Corp. of China control of a major utility in Chile was announced last year but not included in the data because it hasn’t been finalized.

For the region’s leaders, Chinese loans for big ticket infrastructure projects are hard to resist. Interest rates are low and unlike loans from the World Bank and IMF there are fewer strings attached and approval is faster, allowing leaders to tout accomplishments in time for the next election.

Even Colombia — Washington’s staunchest regional ally and a country that was cool to China’s entreaties — recently jumped on the bandwagon. Last year, a consortium including China Harbour Engineering Company broke ground on the capital Bogota’s first metro, a $3.9 billion project. No American firms placed bids for the project, which did not directly benefit from any Chinese loans.

U.S. officials have tried to push back, pointing out that U.S. overseas assistance is longstanding and more transparent.

“Beijing's assistance in the region is generally aimed at advancing the People's Republic of China's commercial or political interests,” the State Department's Bureau of Western Hemisphere Affairs said in a statement.

In January, at the end of the Trump administration, the U.S. International Development Finance Corporation signed an unprecedented agreement with Ecuador to finance up to $2.8 billion in infrastructure projects, money that it said could be used to “refinance predatory Chinese debt.”

But the DFC’s total funding — $60 billion — pale in comparison to the $1 trillion that China has earmarked for its “Belt and Road” initiative to expand influence around the world.

The U.S. loan package to Ecuador was significant because it also would require the government to privatize oil and infrastructure assets and to ban Chinese technology.

“This definitely would limit China's influence,” said Myers. “But by burdening future generations with more debt, and encouraging the use of fossil fuels, does it really help Ecuador in the long run? If it doesn't, then it could backfire against the U.S.”


Associated Press writer Joe McDonald in Beijing contributed to this report.


Joshua Goodman on Twitter: @APJoshGoodman

7 Healthcare Stocks Delivering Innovation in 2021

We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.

Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.

However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.

That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.

View the "7 Healthcare Stocks Delivering Innovation in 2021".

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Sempra Energy (SRE)2.5$134.28+0.8%3.28%10.41Buy$144.55
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.